AR and nonpapillary renal cell carcinoma: Our findings suggest that targeting the AHR could hold therapeutic potential in ccRCC; the activation of this receptor, despite the constitutive HIF1A triggering, is shown to potentiate the tumour suppressor behaviour of both the AR and RB1.